Clinical Trial

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Study acronym: ZAP-DENGUE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09-30 -> 2027-08-31 2026-07-30
minor Completion pushed: 2026-09-30 -> 2027-08-31 2026-07-30
Trial Details
NCT Number NCT04597437
Lead Sponsor George Washington University
Collaborators: Naval Medical Research Center, Clinica de la Costa, Global Disease Research, Universidad Libre de Barranquilla
Conditions Dengue Fever
Enrollment 74 participants
Start Date 2024-03-15
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-29